Arthrosi Therapeutics
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics: Series E Funding Round
Arthrosi Therapeutics has successfully raised $153M in Series E funding, reaching a valuation of $800M.
Company Overview
Developing next-generation gout treatment drug for chronic conditions
Funding Details
The Series E round was led by New Enterprise Associates, with participation from RA Capital.
Company Information
- Headquarters: San Diego, CA
- Founded: 2019
- Employees: 120+
- Category: Biotech
Investment
Arthrosi Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- New Enterprise Associates: Verified investor in Series E
- RA Capital: Verified investor in Series E
Company Info
Investors (2)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free